deucravacitinib (Sotyktu)
Jump to navigation
Jump to search
Indications
- moderate to severe plaque psoriasis[2] & psoriatic arthritis[3]
Contraindications
- avoid use with live virus vaccines
Dosage
Monitor
- serum triglycerides baseline & periodically
- liver function tests baseline & periodically
Adverse effects
- hypersensitivity reactions
- infactions including tuberculosis
- lymphomas
- elevated serum creatine kinase & rhabdomyolysis
- hypertriglyceridemia
- elevated serum ALT, serum AST
- drug adverse effects of tyrosine kinase inhibitor(s)
- drug adverse effects of janus kinase inhibitors
Mechanism of action
- tyrosine kinase-2 inhibitor (TYK2 inhibitor) that inhibits signaling of IL-23, IL-12, & IFN-1, cytokines involved in the pathogenesis of autoimmune diseases[2]
More general terms
References
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION Sotyktu <TM> (deucravacitinib) tablets, for oral use https://packageinserts.bms.com/pi/pi_sotyktu.pdf
- ↑ 2.0 2.1 2.2 Splete H FDA Approves Oral TYK2 Inhibitor Deucravacitinib for Treating Psoriasis. Medscsape. Sept 12, 2022 https://www.medscape.com/viewarticle/980551
- ↑ 3.0 3.1 HealthDay. March 11, 2026 FDA Approves Sotyktu for Adults With Active Psoriatic Arthritis https://www.healthday.com/healthpro-news/skin-health/fda-approves-sotyktu-for-adults-with-active-psoriatic-arthritis
- ↑ Medscape: deucravacitinib (Rx) https://reference.medscape.com/drug/sotyktu-deucravacitinib-4000276